Airdoc 鹰瞳科技 vs Qure.ai
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
Airdoc 鹰瞳科技
HK-listed retinal AI for chronic-disease screening and myopia care
Visit
|
|
|
|---|---|---|
| RECATOOLS Score | 6.8 / 10 | 8.2 / 10 |
| Capability | ||
| Value for money | ||
| Ease of use | ||
| ASEAN readiness | ||
| API quality | ||
| Pricing | Custom | Enterprise |
| Free tier | — | No free tier; enterprise contracts only; trial demos available via sales |
| Paid from | Screening quoted; the PBM myopia device is listed at ¥13,800 | Custom enterprise pricing; contact sales for per-scan or site-licence quotes |
| Has API | ✗ | ✓ |
| Open source | ✗ | ✗ |
| Free to use | ✗ | ✗ |
| Users | — | 34M+ lives impacted across 4,800+ clinical sites in 105+ countries (as of late 2025) |
| Founded | 2015 | 2016 |
| Maker | — | Independent (Series D — Lightspeed, 360 ONE Asset, Merck GHI Fund) |
| Verdict | Airdoc's retinal AI has an unusually strong regulatory record: NMPA Class III approval for diabetic retinopathy in August 2020 and for retinal vein occlusion in April 2025, CE MDR certification for its fundus software, a... |
Qure.ai is one of the most credentialled and widely deployed AI radiology platforms in the world, with a regulatory portfolio (26 FDA-cleared indications, Class IIb CE under EU MDR, CDSCO Class B in India, registrations... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.